

Institutional Biosafety Committee Meeting

01/13/2026

1:30-3:00pm

Zoom Virtual Meeting

Institutional Biosafety Committee Meeting minutes

Meeting Attendance:

- Members in attendance:
 - Elena Demireva
 - Jonathan Hardy
 - Sarah Roosa
 - Jan Patterson Samson
 - Carrie Anglewicz
 - Carolina de Aguiar Ferreira
 - Jamie Willard-Smith

- Members not in attendance:
 - Dave Morgan
 - Raj Kulkarni
 - Michael Bachmann
 - Guo-Qing Song
 - Andras Komaromy
 - Simon Petersen-Jones

- Others in attendance:
 - Chris Colvin
 - Luis Ochoa Carrera

Call to order:

Elena Demireva

Roll call:

Chris Colvin

Discussion of the agenda:

- Approved

Discussion of minutes:

- Approved

Institutional Biosafety Committee Meeting

01/13/2026

1:30-3:00pm

Zoom Virtual Meeting

Registration review:

Study Info

Safety0001399: [REDACTED]

SARS-CoV-2 Infection

Training: Complete for all members listed

NIH III D-2, RG-2, BSL-2+

This registration has been approved with edits. The PI has been asked to clarify the following:

- Viruses – the IBC recommend switching to using 3rd generation lenti viral vectors for increased biosafety.
- rDNA Work Description
 - 1: Correct the first sentence: “The genes inserted in mammalian expression plasmids include lentiviral plasmids”
 - 2: Remove Human or specify human cell lines.
- Supporting Documents
 - Update SOP for viral vector use (refers to 3rd generation but 2nd generation being used).

Study Info

Safety0001412: [REDACTED]

Ocular gene therapy

Training: Complete for all members listed

NIH III-D-4-b, RG-1, BSL-1

This registration has been approved with edits. The PI has been asked to clarify the following:

- rDNA Work Description
 - 1: Add reference material or links for purchased materials.
 - 5: List host range for vectors used.
- Supporting Documents
 - Add evaluation and annual review forms for safer sharps used with infectious materials.

Study Info

Safety0001423: [REDACTED]

Chandler Lab Safety

Training: Complete for all members listed

NIH III D-4-a, RG-1, BSL-1

This registration has been approved with edits. The PI has been asked to clarify the following:

- Biosafety Summary

Institutional Biosafety Committee Meeting

01/13/2026

1:30-3:00pm

Zoom Virtual Meeting

- 2: Include Baculovirus and use of SF21 cells used in the research.
- Virus
 - 1: Add Baculovirus and Lentivirus and include if 2nd or 3rd generation.
- rDNA Usage
 - 4b: Are you using the packaging vectors pMD2.g and psPAX2 with 2nd or 3rd generation virus. They are 2nd gen packaging vectors.
 - 8: Address the three points in the question in terms of probability and consequences. It is important to be aware of and acknowledge potential hazards, and risks that do exist with the use of Lentivirus, FIV and Ad5.
- rDNA Work Description
 - 4: Change to YES for VSV pseudotyping.
 - 5: Address pathogenicity and host range, can remove additional information provided.
 - 7b: Base editors selected, is this a mistake or is this being done? If you are using base editors, please include in the Biosafety Summary.
- Exposure Assessment
 - 1: Remove 3rd paragraph on exposure and containment. Address exposure to Lentivirus and other viral vectors in use as well as exposure to oncogene PIK3CA.

Study Info

Safety0001425: [REDACTED]

[REDACTED] - Functions of Putative ABC1K Protein Kinases

Training: Complete for all members listed

NIH III E-1, RG-1, BSL-1

This registration has been Approved as is.

Study Info

Safety0001429: [REDACTED]

Functional Genomics and Epigenomics

Training: Complete for all members listed

NIH III E-2-a, RG-1, BSL-1

This registration has been approved with edits. The PI has been asked to clarify the following:

- Basic Information
 - 3: Expand summary to include the rationale and primary objectives of the research.
- rDNA Usage
 - 5: Remove Arabidopsis from host section as it is a recipient.

Institutional Biosafety Committee Meeting

01/13/2026

1:30-3:00pm

Zoom Virtual Meeting

- Work Description
 - 2: Add Arabidopsis if receiving recombinant DNA material.
- Exposure Assessment
 - 1: Add information on the potential release of transgenic rice.

New Items:

[Strengthening and Modernizing Biosafety Oversight: Region 3 Listening Session](#)

Previous Submissions:

- Safety0001372 [REDACTED]
- Safety0001387 [REDACTED]
- Safety0001408 [REDACTED]

Next Meeting:

February 18, 2026 10:30 am via zoom